Home » Stocks » OraSure Technologies

OraSure Technologies, Inc. (OSUR)

Stock Price: $14.91 USD 0.14 (0.95%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $14.90 -0.01 (-0.07%) Oct 23, 7:50 PM

Stock Price Chart

Key Info

Market Cap 1.07B
Revenue (ttm) 146.51M
Net Income (ttm) -2.31M
Shares Out 71.56M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $14.91
Previous Close $14.77
Change ($) 0.14
Change (%) 0.95%
Day's Open 14.77
Day's Range 14.60 - 15.00
Day's Volume 1,134,284
52-Week Range 5.23 - 19.75

More Stats

Market Cap 1.07B
Enterprise Value 817.31M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 71.56M
Float 70.82M
EPS (basic) -0.03
EPS (diluted) -0.04
FCF / Share -0.11
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.87M
Short Ratio 2.75
Short % of Float 9.70%
Beta 0.43
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.28
PB Ratio 2.77
Revenue 146.51M
Operating Income -10.46M
Net Income -2.31M
Free Cash Flow -6.88M
Net Cash 249.63M
Net Cash / Share 3.49
Gross Margin 64.01%
Operating Margin -7.14%
Profit Margin -1.60%
FCF Margin -4.70%
ROA -1.61%
ROE -0.69%
ROIC 1.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 3
Overweight 1
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$19.29*
(29.38% upside)
Low
13.0
Current: $14.91
High
32.0
Target: 19.29
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue15518216712812010698.9487.8281.8875.02
Revenue Growth-14.93%8.79%30.32%7.08%12.45%7.6%12.66%7.25%9.15%-
Gross Profit94.5811498.9688.0380.2966.6258.5955.5751.7247.36
Operating Income8.4628.4340.2420.278.06-4.80-12.16-16.27-9.40-3.35
Net Income16.6620.4030.9519.728.17-4.61-11.19-15.12-8.84-3.50
Shares Outstanding61.6861.1159.0555.6256.4055.9555.5651.4646.9146.19
Earnings Per Share0.270.330.510.350.14-0.08-0.20-0.29-0.19-0.08
EPS Growth-18.18%-35.29%45.71%150%------
Operating Cash Flow9.8039.0928.1624.6015.777.538.39-5.37-2.993.89
Capital Expenditures-9.31-6.34-4.34-4.35-3.74-3.01-2.46-2.02-2.51-6.61
Free Cash Flow0.4932.7523.8220.2512.034.525.92-7.39-5.50-2.72
Cash & Equivalents15615715612110197.8793.1987.8923.8875.74
Total Debt7.22-------7.297.79
Net Cash / Debt14915715612110197.8793.1987.8916.5967.95
Assets349316296208189190184191128123
Liabilities42.1532.1938.1222.0929.8930.9323.1021.1227.6119.68
Book Value307283258186159159161170100103
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name OraSure Technologies, Inc.
Country United States
Employees 472
CEO Stephen S. Tang

Stock Information

Ticker Symbol OSUR
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: OSUR
IPO Date November 12, 1986

Description

OraSure Technologies, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, and OraSure QuickFlu Rapid Flu A&B test; OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; tuberculosis products; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND services, a suite of genomic services. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 2000 and is based in Bethlehem, Pennsylvania.